Wolfe Research analyst Andy Chen initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Outperform rating.
Wolfe Research Initiates Coverage On Akero Therapeutics With Outperform Rating
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.